A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors.
Filippo G. De Braud
Research Funding - Boehringer Ingelheim
Stefano Cascinu
Consultant or Advisory Role - Amgen; Pfizer; Roche
Research Funding - Merck
Gianluca Spitaleri
No relevant relationships to disclose
Korinna Pilz
Employment or Leadership Position - Boehringer Ingelheim
Laura Clementi
Employment or Leadership Position - Boehringer Ingelheim
Dan Liu
Employment or Leadership Position - Boehringer Ingelheim
Patricia Glomb
Employment or Leadership Position - Boehringer Ingelheim
Tommaso De Pas
No relevant relationships to disclose